Sign In
Buy BYSI
$1.15
+0.0200 (+1.77%)
At Close: Jul 31, 2026
Cell Journals Publishes BeyondSpring’s New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation
12:00pm, Tuesday, 08'th Oct 2019
NEW YORK, Oct. 08, 2019 -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today.
BeyondSpring Presents Novel Trial Design for DUBLIN-3 Study BPI-2358-103 at ESMO Congress 2019
12:00pm, Tuesday, 01'st Oct 2019
NEW YORK, Oct. 01, 2019 -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immune-oncology cancer therapies, today.
